Abstract 192P
Background
Lung cancer is a disease that ranks among the first in incidence and mortality in Mexico and worldwide. Neuroendocrine tumors (NETs) have been studied for their neurological and endocrine characteristics; NETs are characterized by having active autocrine/paracrine communication with the microenvironment. Serotonin is precursor of melatonin, an indolamine that can exert immunomodulatory effects and is considered one of the molecules of the neuro-immuno-endocrine axis. The transmembrane protein death ligand 1 (PD-L1) is overexpressed in some types of cancer cells, giving them the ability to camouflage themselves against the immune system. The activation PD-1/PD-L1 are responsible for the proliferation, activation, and cytotoxic secretion of T cells in cancer to generate the antitumor immune response.
Methods
In this work neuroendocrine A549 cells were obtained by two different transdifferentiation methodologies for 72 hours with cAMP inducers in DMEM with 2% fetal bovine serum (NED2%) and without fetal bovine serum (NEDsSFB). This differentiation was corroborated through the evaluation of morphology by light microscopy and the expression of specific markers Chromogranin (CgA) and Synaptophysin (Syn) by rt-PCR. The expression of PD-L1 was assessed in A549 cells, NED2% and NEDsSFB groups by rt-PCR and flow cytometry. A co-culture was performed with the neuroendocrine models with T lymphocytes to observe the cytotoxic effect for 24 hours.
Results
The results showed a new neuroendocrine model, suggest an inhibitory effect in proliferation of melatonin and serotonin from concentrations of 2.5 mM and 0.5 μM respectively in both neuroendocrine models at 24 and 48 hours. It is confirmed for the first time the presence of PD-L1 in the neuroendocrine phenotypes cells of A549 (NED2% and NEDsSFB) and thus a mechanism for evasion of the immune system can be proposed.
Conclusions
We conclude with the development of a new neuroendocrine model as well as the possible mechanism of the decrease in the cytotoxic effect of T lymphocytes in neuroendocrine models.
Legal entity responsible for the study
Universidad Autónoma de Querétaro.
Funding
Universidad Autónoma de Querétaro Conahcyt.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract